Takeda Pharma (TKPYY) 24.4200 $TKPYY
Muscular Dystrophy Pipeline Report 2015 - 21 Companies & 47 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89rk9v/muscular) has announced the addition of the "Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - aTyr Pharma, Inc. - Benitec Biopharma Limited - Bioblast Pharma Ltd. - BioMarin Pharmaceutical Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Fate Therapeutics, Inc. - Genethon - Genzyme Corporation - Isis Pharmaceuticals, Inc. - Marina Biotech, Inc. - Novogen Limited - PolyNovo Limited - Prothelia, Inc. - SanBio, Inc. - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Valentia Biopharma S.L. For more information visit http://www.researchandmarkets.com/research/89rk9v/muscular
FATE: 7.25 (unch), BMRN: 141.67 (+1.54), ISIS: 53.50 (+0.42), SRPT: 30.02 (+0.66), XLRN: 30.03 (+0.20)
Overactive Bladder Therapeutics Pipeline Review, H1 2015 - 23 Companies & 32 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb7727/overactive) has announced the addition of the "Overactive Bladder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Allergan, Inc. - Asahi Kasei Pharma Corp. - Astellas Pharma Inc. - Dong-A Socio Group - FemmePharma Global Healthcare, Inc. - Ferring International Center S.A. - Hydra Biosciences, Inc. - Ion Channel Innovations, LLC - Ipsen S.A. - Jeil Pharmaceutical Co., Ltd. - Laboratorios SALVAT S.A. - Lipella Pharmaceuticals, Inc. - Merck & Co., Inc. - Mezzion Pharma Co. Ltd. - MI.TO. Technology S.r.L. - NeuroSearch A/S - Recordati S.p.A. - Sanofi - Takeda Pharmaceutical Company Limited - TARIS BioMedical, Inc. - TheraVida, Inc. - Toray Industries, Inc. Drug Profiles - (mirabegron solifenacin succinate) - abobotulinumtoxin A - ADX-71441 - DA-8010 - FE-999309 - HC-067047 - JLP-1207 - mirabegron ER - NS-19504 - onabotulinumtoxin A liposomal - oxybutynin chloride - oxybutynin hydrochloride - Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - pVAX-hSlo - REC-0438 - SAR-244181 - senrebotase - Small Molecule to Agonize GABAB Receptor for Overactive Bladder and Pain - Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder - Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Small Molecules to Antagonize TRPM8 for Overactive Bladder and Pain - Small Molecules to Antagonize TRPV1 for Overactive Bladder - solifenacin succinate - solifenacin succinate - tacrolimus liposomal - tarafenacin - TD-302 - THVD-201 - THVD-202 - udenafil - vibegron For more information visit http://www.researchandmarkets.com/research/gb7727/overactive
AGN: 312.13 (+8.03), MRK: 57.95 (+0.57)
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles
M2 - Thu Jul 09, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdk8kj/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Advenchen Laboratories, LLC - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Blueprint Medicines - Boston Biomedical, Inc. - Chipscreen Biosciences Ltd - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Jiangsu Hengrui Medicine Co., Ltd. - Natco Pharma Limited - Nerviano Medical Sciences S.r.l. - Novartis AG - Otsuka Holdings Co., Ltd. - Plexxikon Inc. - Synta Pharmaceuticals Corp. - Takeda Pharmaceutical Company Limited - Threshold Pharmaceuticals, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alpelisib - apatinib - BBI-503 - binimetinib - BLU-285 - buparlisib hydrochloride - crenolanib besylate - CS-2164 - DCC-2618 - evofosfamide - ganetespib - LOP-628 - masitinib - motesanib diphosphate - nilotinib - NMSP-088 - NRCAN-019 - onalespib - OPB-51602 - pazopanib hydrochloride - PLX-3397 - ponatinib hydrochloride - quizartinib dihydrochloride - SF-1126 - SHR-1020 - Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - vemurafenib For more information visit http://www.researchandmarkets.com/research/kd...intestinal
BPMC: 28.02 (+2.16), GSK: 42.45 (+0.65), SNTA: 2.16 (-0.01), ARRY: 6.84 (+0.09), NVS: 103.22 (+3.20)
Gouty Arthritis (Gout) Pipeline Review, H1 2015 - 20 Companies & 37 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zcbqd/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/7z..._arthritis
AZN: 66.45 (+1.90), CBAY: 2.68 (-0.01)
Sjogren's Syndrome - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b2hzcp/sjogrens) has announced the addition of the "Sjogren's Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sjogren's Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sjogren's Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aegera Therapeutics Inc. - Amgen Inc. - Bristol-Myers Squibb Company - MedImmune, LLC - Novartis AG - Takeda Pharmaceutical Company Limited - Toleranzia AB For more information visit http://www.researchandmarkets.com/research/b2hzcp/sjogrens
AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), NVS: 103.22 (+3.20)
Guillain-Barre Syndrome - Pipeline Review, H1 2015: 4 Drug Profiles from 2 Companies
M2 - Wed Jun 24, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bb4scj/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Guillain-Barre Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Guillain-Barre Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited Drug Profiles - Coversin - eculizumab - immune globulin (human) - Peptide for Cholera and Guillain-Barre Syndrome For more information visit http://www.researchandmarkets.com/research/bb...llainbarre
ALXN: 192.53 (+4.37)
Anavex Strengthens Board of Directors
GlobeNewswire - Thu Jun 18, 6:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Steffen Thomas, PhD, to its Board of Directors. Dr. Thomas has 15 years of experience in intellectual property, patent law and proprietary technology rights as well as significant expertise in small molecule pharmaceuticals.
Legal-Bay Lawsuit Settlement Funding to Increase Funding Amounts on Pradaxa and Actos Cases
PR Newswire - Thu Jun 18, 4:00AM CDT
Legal-Bay LLC, the Lawsuit Settlement Funding Company, announced today that they are increasing their pre-settlement and settlement funding amounts on all Pradaxa and Actos cases based on the recent settlements by Actos manufacturer Takeda Pharmaceutical Co. and Pradaxa manufacturer Boehringer Ingelheim. Boehringer Ingelheim announced their $650MM settlement on all of their 4,000 cases in state and federal courts over the blood thinner, Pradaxa, resulting in approximately $150K average settlement awards. The Federal Pradaxa lawsuits were consolidated into multidistrict litigation in August of 2012 in the U.S. District Court for the Southern District of Illinois under Judge David R. Herndon (MDL 2385). However, according to legal reports, other consolidated state proceedings also took place in California, Connecticut, Delaware, and Missouri. Lawyers from the jurisdictions worked together to achieve the settlement. Boehringer Ingelheim, despite agreeing to the settlement, denied any wrongdoing, stating they believed the settlement allows their company "to avoid the distraction and uncertainty of protracted litigation over years and years."
Septic Shock Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Tue Jun 16, 5:31AM CDT
The report "Septic Shock - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Septic Shock. Septic shock is life-threatening low blood pressure (shock) due to sepsis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Septic Shock with 30 market data tables and 14 figures, spread across 77 pages is available at http://www.rnrmarketresearch.com/septic-shock...eport.html .
CGEN: 6.63 (+0.06)
AstraZeneca Presents Phase III Data on Gout Drug Lesinurad - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 3:40PM CDT
AstraZeneca (AZN) presented data from a phase III study on gout candidate, lesinurad, at the annual congress of the European League Against Rheumatism.
GILD: 113.74 (+0.38), AZN: 66.45 (+1.90)
Chikungunya - Pipeline Review, H1 2015
M2 - Fri Jun 12, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bhh6h/chikungunya) has announced the addition of the "Chikungunya - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chikungunya, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chikungunya and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Abivax - Arbovax - Bharat Biotech International - Indian Immunologicals - Inovio Pharmaceuticals - Integral Molecular. - Merck & Co. - PaxVax - Profectus BioSciences - Takeda Pharmaceutical Company - Themis Bioscience For more information visit http://www.researchandmarkets.com/research/3b...hikungunya
INO: 7.46 (+0.19), MRK: 57.95 (+0.57)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015 - Profiles of 90 Companies
M2 - Thu Jun 11, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4w5fzl/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - B-Cell Non-Hodgkin Lymphoma Overview - Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance - B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment - Drug Profiles - B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates - B-Cell Non-Hodgkin Lymphoma - Dormant Projects - B-Cell Non-Hodgkin Lymphoma - Discontinued Products - B-Cell Non-Hodgkin Lymphoma - Product Development Milestones - Appendix Companies Mentioned - Affimed Therapeutics AG - Bristol-Myers Squibb Company - Emergent BioSolutions Inc. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - ImmunoGen, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - MorphoSys AG - Nordic Nanovector AS - Portola Pharmaceuticals, Inc. - Priaxon AG - ProNAi Therapeutics, Inc. - Redx Pharma Ltd - Regeneron Pharmaceuticals, Inc. - Respiratorius AB - Rhizen Pharmaceuticals SA - Sandoz Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4w5fzl/bcell
PTLA: 46.44 (+1.05), EBS: 33.85 (+1.10), IMGN: 14.44 (+0.25), TGTX: 18.21 (+0.08), EPZM: 23.42 (+0.45), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), IDRA: 3.49 (+0.05), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), MRTX: 31.67 (+0.81), REGN: 526.01 (+16.98)
Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions
PR Newswire Europe - Fri Jun 05, 4:36PM CDT
Takeda Pharmaceutical Company Limited, ("Takeda" today announced additional post-hoc analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) outcomes trial (CVOT), which assessed patients with Type 2 diabetes who were at a high CV risk due to recent acute coronary syndrome (ACS). During an oral presentation at the American Diabetes Association's 75th Scientific Sessions in Boston, Massachusetts, data from EXAMINE indicated that composite rates of major adverse cardiac events (MACE) were similar for alogliptin compared with placebo in patients taking angiotensin-converting enzyme (ACE) inhibitors [11.4% vs. 11.8%, HR = 0.97, 95% CI, 0.79 - 1.19, p=0.76]. The data also suggested that there were no significant differences for rates of CV death or hospitalized heart failure (HHF) on alogliptin compared to placebo in ACE inhibitor treated patients. Additional post-hoc analyses presented from the EXAMINE data showed that alogliptin compared with placebo did not significantly increase the incidence of cardiac ischemic events [24.6 vs. 25.1, HR=0.98, 95% CI, 0.87 - 1.10, p=0.72] and cardiovascular hospitalizations [16.4 vs. 16.0, HR=1.02, 95% CI, 0.89 - 1.17, p=0.73].
Hyperuricemia - Pipeline Review, H1 2015
M2 - Fri Jun 05, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7s7l4f/hyperuricemia) has announced the addition of the "Hyperuricemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - CymaBay Therapeutics, Inc. - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nippon Chemiphar Co., Ltd. - Polaris Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - arhalofenate - febuxostat - febuxostat XR - JPH-367 - KGO-2142 - KGO-2173 - KUX-1151 - LC-350189 - NC-2500 - pegadricase - RDEA-3170 - Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - XEN-102 For more information visit http://www.researchandmarkets.com/research/7s...eruricemia
AZN: 66.45 (+1.90), CBAY: 2.68 (-0.01)
Rotavirus Infections - Pipeline Review, H1 2015
M2 - Fri Jun 05, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m2366v/rotavirus) has announced the addition of the "Rotavirus Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Beijing Minhai Biotechnology - Biological E. - CureVac - Medicago - Seek - Serum Institute of India - Shantha Biotechnics - Sinovac Biotech - Takeda Pharmaceutical Company For more information visit http://www.researchandmarkets.com/research/m2366v/rotavirus
SVA: 5.26 (+0.02)
Takeda Announces Consolidation of U.S. Vaccine Sites in Boston/Cambridge Area
Business Wire - Tue Jun 02, 11:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda" will consolidate its Vaccine Business Unit (VBU) operations by establishing global and regional hubs as the organization continues to grow and advance its important vaccine programs in norovirus, dengue and seasonal influenza.
EC clears Boehringer Ingelheim's Synjardy
Seeking Alpha - at Seeking Alpha - Thu May 28, 9:22AM CDT
ABT: 49.93 (+0.74), TNDM: 11.47 (+0.28), VTAE: 10.26 (-0.25), LLY: 88.29 (+0.81), ALR: 52.77 (+0.40), MNKD: 5.38 (+0.25), HPTX: 45.99 (+0.02), JNJ: 99.53 (+1.13), NVO: 57.68 (+2.91), MRK: 57.95 (+0.57), SNY: 51.49 (+2.71), VKTX: 6.95 (-0.10)
3 Drug Stocks Prescribed for Portfolio Growth - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 27, 8:54AM CDT
Stocks with Growth Style Scores of A or B when combined with Zacks Rank #1 or #2 offer the best investment opportunities in the growth investing space.
ACT: 298.98 (-2.94), VRX: 232.32 (+8.93), PFE: 34.36 (+0.50), ABBV: 69.23 (+1.26), ANAC: 84.61 (+1.95), HSP: 89.15 (+0.02)
Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis 2014 - 2020
M2 - Tue May 26, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ds5jgv/peptide) has announced the addition of the "Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global peptide therapeutics market is largely concentrated in the western countries of North America and Europe, which account for more than 60% of the market share. Although these regions are currently the largest market segments, the compounded annual growth rate of the market in these regions is expected to be slower as compared to Asia Pacific. India, China and Japan are major countries driving the peptide therapeutics market in the Asia Pacific region. Japan is the second-largest individual pharmaceutical market, while India and China have large patient population due to high disease prevalence. Rapidly developing economy and increasing awareness about various disease treatments are other factors driving the market. India and China have emerged as major peptide API suppliers globally. Patent expiry has been the prime factor impeding market growth; while at the same time has also allowed deeper market penetration in low and middle income countries. The market is also restrained due to unavailability of convenient routes of drug administration, and lower drug stability at room temperature. Scientists, however, are trying to overcome these drawbacks through consistent research and development. With an escalating number of peptide therapeutic drug approvals and consistent launch of generics, the demand for peptide APIs is expected to rise in the near future. Hence, API manufacturers are trying to optimize economies of scale to reduce costs and also meet the rising peptide API demand. Thus, the supply side of the peptide therapeutics value chain would decide the fate of the global market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Peptide Therapeutics Market Overview Chapter 4 Global Peptide Therapeutics Market, by Applications Chapter 5 Global Peptide Therapeutics Market, by Route of Administration Chapter 6 Global Peptide Therapeutics Market, by Marketing Status Chapter 7 Global Peptide Therapeutics Pipeline Overview Chapter 8 Global Peptide Therapeutics Market, by Geography Chapter 9 Recommendations Chapter 10 Company Profiles - Amgen, Inc. - AstraZeneca plc - Bachem Holding AG - CordenPharma International GmbH - Eli Lilly and Company - Ipsen S.A. - Lonza Group Ltd. - Merck & Co., Inc. - Novartis AG - Novo Nordisk A/S - PolyPeptide Group - Roche Holdings AG - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/ds5jgv/peptide
NVO: 57.68 (+2.91), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), AMGN: 154.10 (+2.79), TEVA: 61.38 (-0.75), LLY: 88.29 (+0.81), NVS: 103.22 (+3.20)
Muscular Dystrophy Pipeline Report 2015 - 21 Companies & 47 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89rk9v/muscular) has announced the addition of the "Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - aTyr Pharma, Inc. - Benitec Biopharma Limited - Bioblast Pharma Ltd. - BioMarin Pharmaceutical Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Fate Therapeutics, Inc. - Genethon - Genzyme Corporation - Isis Pharmaceuticals, Inc. - Marina Biotech, Inc. - Novogen Limited - PolyNovo Limited - Prothelia, Inc. - SanBio, Inc. - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Valentia Biopharma S.L. For more information visit http://www.researchandmarkets.com/research/89rk9v/muscular
FATE: 7.25 (unch), BMRN: 141.67 (+1.54), ISIS: 53.50 (+0.42), SRPT: 30.02 (+0.66), XLRN: 30.03 (+0.20)
Overactive Bladder Therapeutics Pipeline Review, H1 2015 - 23 Companies & 32 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb7727/overactive) has announced the addition of the "Overactive Bladder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Allergan, Inc. - Asahi Kasei Pharma Corp. - Astellas Pharma Inc. - Dong-A Socio Group - FemmePharma Global Healthcare, Inc. - Ferring International Center S.A. - Hydra Biosciences, Inc. - Ion Channel Innovations, LLC - Ipsen S.A. - Jeil Pharmaceutical Co., Ltd. - Laboratorios SALVAT S.A. - Lipella Pharmaceuticals, Inc. - Merck & Co., Inc. - Mezzion Pharma Co. Ltd. - MI.TO. Technology S.r.L. - NeuroSearch A/S - Recordati S.p.A. - Sanofi - Takeda Pharmaceutical Company Limited - TARIS BioMedical, Inc. - TheraVida, Inc. - Toray Industries, Inc. Drug Profiles - (mirabegron solifenacin succinate) - abobotulinumtoxin A - ADX-71441 - DA-8010 - FE-999309 - HC-067047 - JLP-1207 - mirabegron ER - NS-19504 - onabotulinumtoxin A liposomal - oxybutynin chloride - oxybutynin hydrochloride - Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - pVAX-hSlo - REC-0438 - SAR-244181 - senrebotase - Small Molecule to Agonize GABAB Receptor for Overactive Bladder and Pain - Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder - Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Small Molecules to Antagonize TRPM8 for Overactive Bladder and Pain - Small Molecules to Antagonize TRPV1 for Overactive Bladder - solifenacin succinate - solifenacin succinate - tacrolimus liposomal - tarafenacin - TD-302 - THVD-201 - THVD-202 - udenafil - vibegron For more information visit http://www.researchandmarkets.com/research/gb7727/overactive
AGN: 312.13 (+8.03), MRK: 57.95 (+0.57)
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles
M2 - Thu Jul 09, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdk8kj/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Advenchen Laboratories, LLC - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Blueprint Medicines - Boston Biomedical, Inc. - Chipscreen Biosciences Ltd - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Jiangsu Hengrui Medicine Co., Ltd. - Natco Pharma Limited - Nerviano Medical Sciences S.r.l. - Novartis AG - Otsuka Holdings Co., Ltd. - Plexxikon Inc. - Synta Pharmaceuticals Corp. - Takeda Pharmaceutical Company Limited - Threshold Pharmaceuticals, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alpelisib - apatinib - BBI-503 - binimetinib - BLU-285 - buparlisib hydrochloride - crenolanib besylate - CS-2164 - DCC-2618 - evofosfamide - ganetespib - LOP-628 - masitinib - motesanib diphosphate - nilotinib - NMSP-088 - NRCAN-019 - onalespib - OPB-51602 - pazopanib hydrochloride - PLX-3397 - ponatinib hydrochloride - quizartinib dihydrochloride - SF-1126 - SHR-1020 - Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - vemurafenib For more information visit http://www.researchandmarkets.com/research/kd...intestinal
BPMC: 28.02 (+2.16), GSK: 42.45 (+0.65), SNTA: 2.16 (-0.01), ARRY: 6.84 (+0.09), NVS: 103.22 (+3.20)
Gouty Arthritis (Gout) Pipeline Review, H1 2015 - 20 Companies & 37 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zcbqd/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Celtaxsys, Inc. - CymaBay Therapeutics, Inc. - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - IOmet Pharma - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Omni Bio Pharmaceutical Inc. - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Pharmaceuticals, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited - TWi Pharmaceuticals, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/7z..._arthritis
AZN: 66.45 (+1.90), CBAY: 2.68 (-0.01)
Sjogren's Syndrome - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b2hzcp/sjogrens) has announced the addition of the "Sjogren's Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sjogren's Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sjogren's Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aegera Therapeutics Inc. - Amgen Inc. - Bristol-Myers Squibb Company - MedImmune, LLC - Novartis AG - Takeda Pharmaceutical Company Limited - Toleranzia AB For more information visit http://www.researchandmarkets.com/research/b2hzcp/sjogrens
AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), NVS: 103.22 (+3.20)
Guillain-Barre Syndrome - Pipeline Review, H1 2015: 4 Drug Profiles from 2 Companies
M2 - Wed Jun 24, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bb4scj/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Guillain-Barre Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Guillain-Barre Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited Drug Profiles - Coversin - eculizumab - immune globulin (human) - Peptide for Cholera and Guillain-Barre Syndrome For more information visit http://www.researchandmarkets.com/research/bb...llainbarre
ALXN: 192.53 (+4.37)
Anavex Strengthens Board of Directors
GlobeNewswire - Thu Jun 18, 6:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Steffen Thomas, PhD, to its Board of Directors. Dr. Thomas has 15 years of experience in intellectual property, patent law and proprietary technology rights as well as significant expertise in small molecule pharmaceuticals. Legal-Bay Lawsuit Settlement Funding to Increase Funding Amounts on Pradaxa and Actos Cases
PR Newswire - Thu Jun 18, 4:00AM CDT
Legal-Bay LLC, the Lawsuit Settlement Funding Company, announced today that they are increasing their pre-settlement and settlement funding amounts on all Pradaxa and Actos cases based on the recent settlements by Actos manufacturer Takeda Pharmaceutical Co. and Pradaxa manufacturer Boehringer Ingelheim. Boehringer Ingelheim announced their $650MM settlement on all of their 4,000 cases in state and federal courts over the blood thinner, Pradaxa, resulting in approximately $150K average settlement awards. The Federal Pradaxa lawsuits were consolidated into multidistrict litigation in August of 2012 in the U.S. District Court for the Southern District of Illinois under Judge David R. Herndon (MDL 2385). However, according to legal reports, other consolidated state proceedings also took place in California, Connecticut, Delaware, and Missouri. Lawyers from the jurisdictions worked together to achieve the settlement. Boehringer Ingelheim, despite agreeing to the settlement, denied any wrongdoing, stating they believed the settlement allows their company "to avoid the distraction and uncertainty of protracted litigation over years and years."
Septic Shock Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Tue Jun 16, 5:31AM CDT
The report "Septic Shock - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Septic Shock. Septic shock is life-threatening low blood pressure (shock) due to sepsis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Septic Shock with 30 market data tables and 14 figures, spread across 77 pages is available at http://www.rnrmarketresearch.com/septic-shock...eport.html .
CGEN: 6.63 (+0.06)
AstraZeneca Presents Phase III Data on Gout Drug Lesinurad - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 3:40PM CDT
AstraZeneca (AZN) presented data from a phase III study on gout candidate, lesinurad, at the annual congress of the European League Against Rheumatism.
GILD: 113.74 (+0.38), AZN: 66.45 (+1.90)
Chikungunya - Pipeline Review, H1 2015
M2 - Fri Jun 12, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bhh6h/chikungunya) has announced the addition of the "Chikungunya - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chikungunya, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chikungunya and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Abivax - Arbovax - Bharat Biotech International - Indian Immunologicals - Inovio Pharmaceuticals - Integral Molecular. - Merck & Co. - PaxVax - Profectus BioSciences - Takeda Pharmaceutical Company - Themis Bioscience For more information visit http://www.researchandmarkets.com/research/3b...hikungunya
INO: 7.46 (+0.19), MRK: 57.95 (+0.57)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015 - Profiles of 90 Companies
M2 - Thu Jun 11, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4w5fzl/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - B-Cell Non-Hodgkin Lymphoma Overview - Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance - B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment - Drug Profiles - B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates - B-Cell Non-Hodgkin Lymphoma - Dormant Projects - B-Cell Non-Hodgkin Lymphoma - Discontinued Products - B-Cell Non-Hodgkin Lymphoma - Product Development Milestones - Appendix Companies Mentioned - Affimed Therapeutics AG - Bristol-Myers Squibb Company - Emergent BioSolutions Inc. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - ImmunoGen, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - MorphoSys AG - Nordic Nanovector AS - Portola Pharmaceuticals, Inc. - Priaxon AG - ProNAi Therapeutics, Inc. - Redx Pharma Ltd - Regeneron Pharmaceuticals, Inc. - Respiratorius AB - Rhizen Pharmaceuticals SA - Sandoz Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4w5fzl/bcell
PTLA: 46.44 (+1.05), EBS: 33.85 (+1.10), IMGN: 14.44 (+0.25), TGTX: 18.21 (+0.08), EPZM: 23.42 (+0.45), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), IDRA: 3.49 (+0.05), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), MRTX: 31.67 (+0.81), REGN: 526.01 (+16.98)
Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions
PR Newswire Europe - Fri Jun 05, 4:36PM CDT
Takeda Pharmaceutical Company Limited, ("Takeda"
today announced additional post-hoc analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) outcomes trial (CVOT), which assessed patients with Type 2 diabetes who were at a high CV risk due to recent acute coronary syndrome (ACS). During an oral presentation at the American Diabetes Association's 75th Scientific Sessions in Boston, Massachusetts, data from EXAMINE indicated that composite rates of major adverse cardiac events (MACE) were similar for alogliptin compared with placebo in patients taking angiotensin-converting enzyme (ACE) inhibitors [11.4% vs. 11.8%, HR = 0.97, 95% CI, 0.79 - 1.19, p=0.76]. The data also suggested that there were no significant differences for rates of CV death or hospitalized heart failure (HHF) on alogliptin compared to placebo in ACE inhibitor treated patients. Additional post-hoc analyses presented from the EXAMINE data showed that alogliptin compared with placebo did not significantly increase the incidence of cardiac ischemic events [24.6 vs. 25.1, HR=0.98, 95% CI, 0.87 - 1.10, p=0.72] and cardiovascular hospitalizations [16.4 vs. 16.0, HR=1.02, 95% CI, 0.89 - 1.17, p=0.73]. Hyperuricemia - Pipeline Review, H1 2015
M2 - Fri Jun 05, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7s7l4f/hyperuricemia) has announced the addition of the "Hyperuricemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - CymaBay Therapeutics, Inc. - Kissei Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Nippon Chemiphar Co., Ltd. - Polaris Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - arhalofenate - febuxostat - febuxostat XR - JPH-367 - KGO-2142 - KGO-2173 - KUX-1151 - LC-350189 - NC-2500 - pegadricase - RDEA-3170 - Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - XEN-102 For more information visit http://www.researchandmarkets.com/research/7s...eruricemia
AZN: 66.45 (+1.90), CBAY: 2.68 (-0.01)
Rotavirus Infections - Pipeline Review, H1 2015
M2 - Fri Jun 05, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m2366v/rotavirus) has announced the addition of the "Rotavirus Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Beijing Minhai Biotechnology - Biological E. - CureVac - Medicago - Seek - Serum Institute of India - Shantha Biotechnics - Sinovac Biotech - Takeda Pharmaceutical Company For more information visit http://www.researchandmarkets.com/research/m2366v/rotavirus
SVA: 5.26 (+0.02)
Takeda Announces Consolidation of U.S. Vaccine Sites in Boston/Cambridge Area
Business Wire - Tue Jun 02, 11:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
will consolidate its Vaccine Business Unit (VBU) operations by establishing global and regional hubs as the organization continues to grow and advance its important vaccine programs in norovirus, dengue and seasonal influenza. EC clears Boehringer Ingelheim's Synjardy
Seeking Alpha - at Seeking Alpha - Thu May 28, 9:22AM CDT
ABT: 49.93 (+0.74), TNDM: 11.47 (+0.28), VTAE: 10.26 (-0.25), LLY: 88.29 (+0.81), ALR: 52.77 (+0.40), MNKD: 5.38 (+0.25), HPTX: 45.99 (+0.02), JNJ: 99.53 (+1.13), NVO: 57.68 (+2.91), MRK: 57.95 (+0.57), SNY: 51.49 (+2.71), VKTX: 6.95 (-0.10)
3 Drug Stocks Prescribed for Portfolio Growth - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 27, 8:54AM CDT
Stocks with Growth Style Scores of A or B when combined with Zacks Rank #1 or #2 offer the best investment opportunities in the growth investing space.
ACT: 298.98 (-2.94), VRX: 232.32 (+8.93), PFE: 34.36 (+0.50), ABBV: 69.23 (+1.26), ANAC: 84.61 (+1.95), HSP: 89.15 (+0.02)
Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis 2014 - 2020
M2 - Tue May 26, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ds5jgv/peptide) has announced the addition of the "Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global peptide therapeutics market is largely concentrated in the western countries of North America and Europe, which account for more than 60% of the market share. Although these regions are currently the largest market segments, the compounded annual growth rate of the market in these regions is expected to be slower as compared to Asia Pacific. India, China and Japan are major countries driving the peptide therapeutics market in the Asia Pacific region. Japan is the second-largest individual pharmaceutical market, while India and China have large patient population due to high disease prevalence. Rapidly developing economy and increasing awareness about various disease treatments are other factors driving the market. India and China have emerged as major peptide API suppliers globally. Patent expiry has been the prime factor impeding market growth; while at the same time has also allowed deeper market penetration in low and middle income countries. The market is also restrained due to unavailability of convenient routes of drug administration, and lower drug stability at room temperature. Scientists, however, are trying to overcome these drawbacks through consistent research and development. With an escalating number of peptide therapeutic drug approvals and consistent launch of generics, the demand for peptide APIs is expected to rise in the near future. Hence, API manufacturers are trying to optimize economies of scale to reduce costs and also meet the rising peptide API demand. Thus, the supply side of the peptide therapeutics value chain would decide the fate of the global market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Peptide Therapeutics Market Overview Chapter 4 Global Peptide Therapeutics Market, by Applications Chapter 5 Global Peptide Therapeutics Market, by Route of Administration Chapter 6 Global Peptide Therapeutics Market, by Marketing Status Chapter 7 Global Peptide Therapeutics Pipeline Overview Chapter 8 Global Peptide Therapeutics Market, by Geography Chapter 9 Recommendations Chapter 10 Company Profiles - Amgen, Inc. - AstraZeneca plc - Bachem Holding AG - CordenPharma International GmbH - Eli Lilly and Company - Ipsen S.A. - Lonza Group Ltd. - Merck & Co., Inc. - Novartis AG - Novo Nordisk A/S - PolyPeptide Group - Roche Holdings AG - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/ds5jgv/peptide
NVO: 57.68 (+2.91), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), AMGN: 154.10 (+2.79), TEVA: 61.38 (-0.75), LLY: 88.29 (+0.81), NVS: 103.22 (+3.20)
